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Abstract
Background: Maternal prenatal depressive or anxiety symptoms are associated with adverse maternal and infant
health outcomes. With prevalence rates of maternal prenatal depression and anxiety ranging between 10 and 20%,
attempts to identify effective interventions to reduce symptoms are priority. There are indications that probiotics
can reduce symptoms of maternal depression or anxiety. Probiotics ingested by the mother may thus offer a promising
and accessible intervention to complement existing treatments.
Methods: The Probiotics in Pregnancy (PIP) pilot trial is a double-blind, placebo-controlled, randomized pilot trial. While
one group orally consumes a probiotic mixture (Ecologic® Barrier; 2,5 × 109 colony forming units/g; 2 g; daily), the other
group consumes a placebo, from between 26 and 30 weeks gestation until delivery. Subjects are randomly allocated
(1:1) to the intervention or placebo group. Forty healthy pregnant women with symptoms of depression or
anxiety and uncomplicated pregnancies at randomization will be included. The primary aim is to determine
the feasibility and acceptability of a probiotic trial to reduce symptoms of maternal depression or anxiety in
pregnancy. The secondary aim is to exploratorily compare the potential effect of probiotics, compared to placebo, on
depressive and/or anxiety symptoms, maternal stress (i.e. reported/hair cortisol), maternal vaginal and intestinal
microbiota, and by possibly affecting maternal mood and microbiota, maternal bonding to offspring, infant
microbiota and infant crying.
Discussion: Results of this pilot trial will help determine whether or not to proceed with a full trial after the
pilot trial, and if so, whether revisions should be made to the study protocol and procedures before conducting a full
randomized controlled trial. Additionally, they are expected to provide insights into whether changes in psychological,
behavioral and biological parameters can be attributed to the probiotic intervention.
Trial registration: Netherlands Trial Register, NTR6219. Registered on 28 February 2017.
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Background
Pregnancy can be an exhilarating time for expectant
mothers. However, pregnancy can also be accompanied
by sadness and worry, as 10–20% of pregnant mothers
report anxiety and depressive symptoms [1, 2]. Counsel-
ing and medical treatments are effective to reduce symp-
toms of maternal prenatal depression or anxiety.
However, relatively few women engage in treatment [2,
3]. This can, in part, be explained by reluctance to use
medication prenatally, therapies being inaccessible to
women and/or long waiting lists for treatment [4, 5].
Hence, there is a need for safe, accessible and effective
complementary interventions to treat maternal prenatal
depression and anxiety. Probiotics may reduce symp-
toms of depression and anxiety in people with elevated
levels of anxiety and/or depression [6]. In the current
study, we will investigate the feasibility and acceptability
of conducting a probiotic intervention from 26 to 30
weeks gestation until birth, for reducing maternal pre-
natal symptoms of depression or anxiety.
Probiotics for maternal mood
Probiotics are live organisms that, consumed in adequate
amounts, confer a health benefit to the host [7]. Probio-
tics, with their anti-inflammatory and neuro-regulatory
properties, may improve gut microbiota composition
and functioning, consequently improving mood [8–10].
Previous systematic reviews found that probiotics can
indeed reduce depressive symptoms [11–13]. However,
the recent high-quality systematic review by Ng et al. in
2018 [11] concluded that probiotics are only effective in
non-pregnant people with pre-existing symptoms of
anxiety or depression. In pregnant women, a recent ran-
domized controlled trial (RCT) with a low risk of bias
showed that a probiotic intervention during the perinatal
period significantly reduced symptoms of maternal de-
pression and anxiety postpartum, compared to mothers
receiving a placebo [14, 15]. To date, no studies have
investigated the potential effectiveness of probiotics
during pregnancy to improve maternal mood.
RCTs are judged the “gold standard” to evaluate the
therapeutic efficacy of psychological treatments [16, 17].
The success of a RCT in pregnant women largely depends
on two factors: women’s willingness to participate in the
study and compliance to the intervention during the trial
[18, 19]. In order to increase chances of success of a poten-
tial future RCT, it is of value to first assess feasibility (i.e.
whether the future trial can be done) and acceptability (i.e.
participants’ adherence and satisfaction with the study) of
the study protocol by employing a pilot trial [20, 21].
Objectives
The main aim of this pilot trial is to evaluate the feasibility
and acceptability of conducting a definitive RCT among
pregnant women with symptoms of depression or anxiety.
Feasibility is evaluated in terms of (A) recruitment and (B)
retention, and acceptability is evaluated in terms of (C)
compliance and (D) participants’ experiences of partici-
pating in the study. The primary objectives are to quanti-
tatively and qualitatively assess (A) the proportion of
pregnant women with depressive and/or anxiety symp-
toms accepting the invitation to participate in the pilot
trial and the reasons why (quantitative and qualitative),
(B) the proportion of women who complete the study
(quantitative), (C) adherence rates to the intervention
schedule (i.e. probiotic/placebo intake, questionnaires and
biological sample collection) (quantitative) and (D) partici-
pants’ impressions and experiences during the pilot trial
(quantitative). The secondary aim is to exploratorily
compare the potential effect of probiotics, compared to
placebo, on depressive and/or anxiety symptoms, maternal
stress (i.e. reported and hair cortisol), maternal vaginal
and intestinal microbiota, and by possibly affecting mater-
nal mood and microbiota, maternal bonding to offspring,
infant microbiota and infant crying. The purpose of
collecting these secondary outcomes will be to ensure that
the potential effects of probiotics on maternal mood, and
the mechanisms underlying these potential effects, can be
assessed appropriately in a future definitive RCT.
Methods
Trial design
This probiotic intervention project in mothers and their
infants is a double-blind, randomized pilot trial (RCT)
(probiotic intervention versus placebo). Forty healthy
pregnant women (≥ 18 years of age) with at least mild
depressive symptoms and/or anxiety in the late second/
third trimester of an uncomplicated pregnancy (≥ 26
and ≤ 30 weeks gestation) will be enrolled in this study (see
Fig. 1). Participants will orally consume a probiotic multi-
species mixture (Ecologic® Barrier; 2,5 × 109 colony forming
units (CFU)/g per dosage; daily dosage 2 g) once daily,
or a placebo, for 8–14 weeks consecutively (depending
on the time of delivery). Detailed information on the inter-
vention components is provided under “Intervention pro-
cedures”. For more information on the protocol items,
please refer to the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) checklist
(Additional file 1).
Study setting and recruitment
Recruitment procedures
Recruitment methods in the pilot will mimic those of a
full RCT. Recruitment will take place in collaboration with
two ultrasound centers (VCN/CVN and Fara), a lactation
consultant practice (Fijn Voeden), two mental health cen-
ters (Praktijk Moeder and Mental health center Jolande
Zewuster) and an academic hospital (Radboud university
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Fig. 1 (See legend on next page.)
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medical center) in the Netherlands. These different cen-
ters and clinics were chosen because they serve ethnically
and socioeconomically diverse, low-class and high-class
populations.
Screening process and participant flow
Potentially eligible women are identified through two
mechanisms: (1) local research advertising and (2) identi-
fication in the research database. Women visiting echo
center Fara (around 200 per month) will receive an e-mail
invitation for an online questionnaire after their 20-week
ultrasound scan. The e-mail will be sent by a Fara
organizational committee member. At the second echo
center (VCN/CVN), women who visit the centers for their
20-week echo will receive a flyer and can sign up to re-
ceive the online questionnaire by providing their e-mail
addresses. Research assistants at the Radboud University
will collect these e-mail addresses and send the women an
e-mail invitation for the online questionnaire. Flyers with
a link to the online questionnaire are placed in the waiting
room at the academic hospital, the lactation consultant
practice and the mental health centers. In this way,
women can directly access the online questionnaire. The
questionnaire forms part of another study investigating
the psychosocial needs of women during pregnancy,
which is approved by the Ethics Committee of the
Faculty of Social Sciences ECSW (registration number:
ECSW2016–1710-42, registration date 19 December 2017).
Women voluntarily give informed consent before filling in
the online questionnaire. The online questionnaire consists
of the Edinburgh Postnatal Depression Scale (EPDS),
State-trait Anxiety Inventory, State (STAI-S), questions on
demographic variables (e.g. general health, maternal life-
style, sociodemographic and economic factors) and open
questions on psychosocial needs, barriers and facilitators to
mental healthcare use. At the end of the online question-
naire the respondent will be asked whether she would want
to be included in a research database. This would entail
that the woman’s contact details are kept securely on the
protected server of the Radboud University. Women agree-
ing to this give permission to be contacted as potential
participants for research in the future. The data on women
not agreeing to be contacted as potential participants for
further research are not used for this study.
From the research database, the Coordinating Investi-
gator (CI) will contact women who have, according to
the STAI-S and EPDS, at least mild symptoms of depres-
sion or anxiety. The CI informs these women about the
PIP pilot trial and inquires whether they would like to
receive information about the PIP pilot trial. When a
woman agrees to receive information, a participant
information booklet is sent to her. If a woman is not
interested in receiving information, her reasons for this
are recorded on a Microsoft Excel spreadsheet chart.
One week after the participant information booklet is
sent, the CI will contact the woman by telephone to
inquire whether she is interested in participating in the
trial. This call is also an opportunity for the woman to
ask any remaining questions about the pilot trial. If the
woman is interested in joining the study, she will be
requested to send the signed informed consent form to
the Radboud University. If a woman does not want to
participate in the study, the CI will inquire about her
reasons for non-participation (see “Qualitative out-
comes”) and will record these on a Microsoft Excel
spreadsheet chart. However, according to the principles
of the Declaration of Helsinki, the CI will also inform
the woman that she is not obligated to reveal her
reason(s) for non-participation.
After signing the informed consent form, women will
be requested to fill in a screening questionnaire online
for assessment of their eligibility (see “Participants” for
inclusion and exclusion criteria). If women are eligible,
the CI will contact them by telephone to administer the
Mini International Neuropsychiatric Interview (MINI).
A woman who scores as “high risk” on the MINI ques-
tionnaire or is otherwise not eligible will be informed
about exclusion from the pilot trial. As stated in the
informed consent form, in the case of a high risk score
the woman’s general practitioner will also be informed
within a maximum of 12 h about the outcome of the
MINI. The remaining eligible women will be informed
about inclusion and a home visit will be scheduled. They
will also be randomized into one of the treatment arms.
Recruitment through centers and clinics and by using
a research database was deemed appropriate for two
reasons. First, it would not put undue pressure on
women to consent to participate in the pilot trial.
Second, it would prevent unnecessary visits by pregnant
women to the Radboud University during the screening
phase, as many of the women visiting the University
would not fall under the eligibility criteria (i.e. the
(See figure on previous page.)
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure displaying the pilot trial design and the outcome
measurements. After screening for eligibility (t-1), women sign the informed consent form and complete the baseline questionnaire (t0).
Participants are then randomized in the probiotic or placebo arm and receive either the probiotic food supplement or placebo. After
randomization, filling in the baseline questionnaire and collecting maternal vaginal and stool samples, women start using either the probiotic food
supplement or placebo. Measurements take place at 26–30weeks of pregnancy (baseline(t0); 34–38weeks of pregnancy (t1); 7 days after birth (t3), and
1month after birth (t4)).
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prevalence rate of elevated symptoms of anxiety and de-
pression in pregnant women is between 10 and 20%).
A total of 2135 women need to be approached for this
trial to reach a sample population of 40 participants (see
Fig. 2). This number was calculated based on the follo-
wing. First, from our own experience, we assume a
response rate of 25% to the e-mail invitation for the
online screening. Second, based on previous studies, we
can expect 15% of all women who filled in the online
questionnaire to screen positive for at least mild symp-
toms of depression or anxiety and who are thus preli-
minarily eligible [22, 23]. Finally, we expect that 50% of
all the preliminarily eligible women interested in parti-
cipating will meet all participation criteria and give
informed consent. The 50% rate is based on previous
studies examining the effect of dietary and psychological
interventions during pregnancy [24, 25]. The expected
total duration of the study from the start (enrolment of
the first participants) to the last participant finishing is
13 months. No target population per site is set; recruit-
ment will continue at all sites until the target population
of 40 women is achieved. Training/information meetings
will be held with organizational committee members at
all involved sites prior to the start of recruitment. Each
site will be monitored by Radboud University staff
through regular telephone calls and e-mail correspon-
dence, and in the case of any recruitment problems,
strategies for solving them will be discussed.
Start of the intervention
Prior to the first home visit, the participant fills in the
baseline questionnaire (see Fig. 1). During the first home
visit, the participants receive the probiotic/placebo
product and kits from the CI who is blinded to the inter-
vention. The participant collects the first stool and
vaginal samples at home prior to the start of taking the
probiotic/placebo product. These samples are kept in
the participant’s freezer and handed over to the CI or
research assistant at time point 1 (t1) or t4. After stool
and vaginal fluid collection, the participant starts with
the probiotic/placebo product intake once per day until
time of delivery.
Inclusion and exclusion criteria
The total sample of 40 healthy pregnant women will be
recruited in the region of Wageningen and Nijmegen,
The Netherlands. In order to be eligible to participate in
this pilot trial, women must meet all of the following
inclusion criteria:
1. At least mild symptoms of depression or anxiety.
2. Start daily probiotic/placebo product intake
between 26 and 30 weeks gestational age and
continue until delivery. The lower limit of ≥ 26
weeks and the upper limit of 30 weeks allow time to
complete at least 8 weeks of probiotic intake prior
to delivery. Gestational age is based on last
menstrual period and the early ultrasound scan.
A potential participant who meets any of the following
exclusion criteria will be excluded from participation in
this pilot trial:
1) Multiple pregnancy (increased obstetric risk).
2) High suicidal risk according to suicidality
subscale score on the MINI (see screening).
3) Illegal drug use.
4) History of psychoses and bipolar disorder.
5) Inflammatory bowel disease (i.e. ulcerative
colitis, Crohn’s disease).
6) Other autoimmune disorders and/or treatment
with immunosuppressive therapy.
7) Known pre-existing diabetes mellitus,
hyperemesis gravidarum, hypertensive disorders
or liver or renal disease.
8) Malignancy and/or treatment with radiation
or chemotherapy.
9) History of major gastro-intestinal surgery
(e.g. colectomy).
10) Hypersensitivity or allergy to any ingredients
in the probiotic/placebo product.
11) History of using oral multi-species probiotic
Ecologic® Barrier.
12) Presently using food containing probiotics
(e.g. Actimel) and not willing to stop these
at least 2 weeks prior to the start of the
probiotic/placebo product intake.
13) No mastery of the Dutch language.
Sample size calculation
The main aim of the PIP pilot trial is to evaluate the
feasibility and acceptability of a probiotic intervention in
pregnant women suffering from depressive and/or
anxiety symptoms. Since the pilot study will lay the basis
for designing a larger RCT, the sample size calculations
are based on a full RCT. An a priori power analysis to
estimate the sample size was conducted using G*Power
3.1. An effect size of f = 0.187 was used for the sample
size calculation, based on the prior studies of Benton
(2007) [26] examining the effect of probiotics on symp-
toms of depression in healthy volunteers with elevated
levels of depression. With a significance level of 5% and
power of 80%, including 60 women per arm (total of
120) would be required to examine probiotic effective-
ness in reducing depressive symptoms. To account for
dropout, poor compliance, antibiotic use around the
time of the intervention period and pregnancy complica-
tions, all of which may negate any potential effects from
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Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram indicating the participant’s flow through the study. After eligibility
screening, women are randomized either to the probiotic or placebo arm. Follow-up measurements take place at 34–38 weeks of pregnancy (T1),
7 days after birth (T3), and 1month after birth (T4). EPDS, Edinburgh Postnatal Depression Scale; LEIDS-R, Leiden Index of Depression Sensitivity-
Revised; PRAQ-R, Pregnancy Related Anxiety Questionnaire-Revised
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the probiotic/placebo product, we estimate that a total
of 150 women would be needed for a full trial. Since the
primary aim of the present pilot trial is to examine feasi-
bility and acceptability, recruiting a total of 40 women
(20 women per arm (~ 27% of a full trial)) would be
adequate for this outcome. No interim analysis of pre-
liminary results will be conducted given the expected
relatively short duration of the pilot study and given that
the study is labeled as minimal-risk research.
Randomization, blinding and treatment allocation
The 40 women will be randomly allocated to either the
probiotic arm or placebo arm. A computer random
number algorithm (1:1 allocation ratio) at Winclove pro-
biotics B.V. will randomize women, using blocks of 4. A
staff member at Winclove Probiotics B.V., who is not
involved in the study, will sequentially label probiotic
boxes (including number sachets with the probiotic or
placebo product). The staff member will also create a
sealed randomization list and sealed code break enve-
lopes per participant in order to keep the trial inves-
tigators unaware of the allocation sequence and
randomization code, and to maintain blinding until the
end of the pilot trial. The randomization code will not
be released until the last participant has finished the
pilot trial. The CI, who is unaware of participant assign-
ment in the allocation sequence, will distribute the
sequentially numbered probiotic boxes. Participants will
be assigned to a numbered box upon order of providing
informed consent. Next to investigators, the participants,
care providers and outcome assessor are blinded to the
participant’s allocation. The Principal Investigator (PI)
has access to the randomization data in case it is neces-
sary to unblind. The blind may be broken for a serious
and unexpected event, if it is essential for the medical
management of subjects, or may provide critical safety
information about the intervention that could have
implications for the ongoing conduct of this trial. Sealed
code break envelopes per participant are accessible
within 24 h. In the event of a code break, the name of
the code breaker, the signature and the date and time
will be recorded on the outside of the envelope.
Intervention procedure
Probiotic/placebo formulations
Participating women will be randomly allocated to either
control group (placebo) or intervention probiotic group
(multispecies probiotic Ecologic® Barrier, Winclove Pro-
biotics B.V.) once daily for 8–14 constituent weeks. The
probiotic food supplement is a freeze-dried powder in
sachets and contains 2,5 × 109 CFU/g. One dose (one sa-
chet) consists of a total of 5,0 × 109 CFU (2 g). The
recommended dosage of the probiotic product of one
sachet per day is in concordance with probiotic dosages
used in previous studies examining Ecologic® Barrier and
other multispecies probiotic products. The number of
bacteria in a dose ranges from 109 to 1010 CFU/dose,
which is the normal amount of bacteria for studies in
healthy volunteers and pregnant women [27–29]. The
probiotic product contains the following bacterial strains:
Bifidobacterium bifidum W23, Bifidobacterium lactis W51,
Bifidobacterium lactis W52, Lactobacillus acidophilus
W37, Lactobacillus brevis W63, Lactobacillus casei W56,
Lactobacillus salivarius W24, Lactococcus lactis W19 and
Lactococcus lactis W58 (total cell count 2.5 × 109/g). In
addition to the bacteria, the probiotic product contains
the carrier of the product: maize starch, maltodex-
trins, inulin and fructo-oligosaccharides (FOS).
Preclinical studies suggest that prebiotics, such as FOS
and inulin, can exert antidepressant and anxiolytic
effects [30, 31]. Therefore, in order to properly assess
potential effects of bacteria on maternal mood, the
placebo intervention includes the same carrier of maize
starch, maltodextrins, inulin and FOS, but no bacteria.
The placebo is indistinguishable from the probiotic
sachets in color, taste and smell (Winclove Probiotics
B.V., The Netherlands).
Intake procedure
Participants in the probiotic and placebo intervention
groups are provided with 108 sachets (one for each day
of the intervention, total of 3,5 months). The contents of
the sachets need to be dissolved in 100 mL water, milk
or yoghurt. The solution containing the probiotic/pla-
cebo is to be ingested orally, preferably on an empty
stomach. The participant will be advised to take the pro-
biotic/placebo 2–3 h after antibiotic ingestion if taking
antibiotics. The sachets are stored at room temperature
in their original package.
The full RCT will not investigate probiotics as a single
treatment, but will explore their properties as a food
supplement in addition to patients’ current treatments, if
applicable. Hence, the use of any kind of co-medication,
therapy (e.g. cognitive behavior therapy) or alternative
therapy (e.g. yoga, mindfulness, tai chi, etc.) is allowed
and will be reported accordingly. Participants are
requested to discontinue any other probiotic (such as
probiotic yoghurts) two weeks prior to the start of
the intake of the probiotic/placebo product and to
refrain from taking any other probiotics during the
whole trial period.
Measurements and outcomes
Primary outcome
The primary outcome will be assessed as follows: feasi-
bility will be assessed in terms of (A) recruitment (quan-
titative and qualitative), (B) retention (quantitative) and
acceptability will be assessed in terms of (C) compliance
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(quantitative) and (D) participants’ impressions and
experiences during the pilot trial (quantitative).
The primary outcome of a full RCT would include
effectiveness of the probiotic, compared to placebo, in
reducing anxiety and depressive symptoms during preg-
nancy. For that reason, key outcome measures of this pilot
study will inform whether or not to proceed with a full trial
after this study, and if so, the revisions that should be made
to the study protocol before conducting a full RCT. These
outcomes include (B) retention rate, (C) compliance (i.e.
proportion of participants taking ≥ 80% probiotic/placebo
and proportion of participants filling in electronic ques-
tionnaires at all time points) and (D) participants’ experi-
ences of participation and perspectives on joining this and
future probiotic trials. Table 1 shows the outcomes,
progression criteria (where applicable), key outcome mea-
sures and time points for each outcome of this pilot study.
Primary outcomes: quantitative
1. Recruitment: the CI will obtain data on the
proportion of women agreeing to participate in the
trial and the site of recruitment from the research
database and Excel spreadsheet chart after
completion of the pilot study and will report the
data on Microsoft Excel spreadsheet charts
(see “Study setting and recruitment”).
2. Retention rate: dropouts and the reasons for
withdrawal if known will be documented by the CI on
Table 1 Primary outcomes, (key) outcome measures, time points for each outcome and progression criteria for a full RCT
Primary quantitative outcomes Outcome measure and time point for each outcome Progression criteria for full RCTa
A) Recruitment 1) The proportion of contacted participants scoring
above the threshold for anxiety or depressive symptoms
and who accept the invitation to participate in the pilot
trial throughout the study
30 participants recruited in 6 months
2) The number of participants recruited at each site No criteria set
B) Retention rate 2) The proportion of participants completing the
study from enrolment (t0) to follow up (t4)*
≥ 90% of enrolled participantsb
C) Compliance 3) The proportion of participants taking ≥ 80%
probiotic/placebo product between t0 and t1*
90% of participantsc
4) The proportion of participants filling in electronic
questionnaires at all time points (t0, t1 and t4)*
90% of participants
5) The proportion of participants filling in the cry
diary at t4
90% of participants
6) The proportion of participants filling in evaluation
form at t4
90% of participants
7) The proportion of participants collecting all maternal
vaginal and microbial samples at t0 and t1
90% of participantsd
8) The proportion of participants collecting all infant
microbial samples at t0 and t1
90% of participants
9) The proportion of participants allowing collection
of hair samples at t4
90% of participants
D) Participants’ impressions
and experiences
1) Experiences and level of acceptability of electronic
questionnaires and collection of biological samples
No criteria set
2) Level of satisfaction (positive/negative aspect) No criteria set
3) Level of satisfaction (execution and organization) No criteria set
4) Level of acceptability of the trial in practice
(perceived burden)*
Mean score of ≤3
5) Level of acceptability of the trial in principle
(future participation)*
Mean score of ≥8
Primary qualitative outcomes
A) Recruitment 1) Participants’ moment of decision to join the
pilot trial
No criteria set
2) Reasons for participation No criteria set
3) Reasons for non-participation No criteria set
aIn case one or more progression criteria are not met, revisions to the study protocol should be considered prior to conducting the full randomized controlled
trial (RCT)
bA rate > 90% is comparable to previous RCTs in pregnant women with depressive and anxiety symptoms [32, 33]
cA rate of intake ≥ 80% is similar to other (pilot) RCTs with probiotics and food supplements in pregnant and non-pregnant individuals [34, 35]
dThe rates of adherence to vaginal and fecal sampling and hair-sampling protocols do not include unforeseen errors, for example, loss of biological samples
due to storage problems, etc
*Key progression criteria
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case report forms (CRFs) throughout the pilot trial.
New participants will not replace dropouts. Data on
the proportion of women who complete the study will
be collected from CRFs at the end of the study (see
“Data management” and “Statistical analysis”).
3. Compliance: the rates of adherence to
probiotic/placebo intake, electronic
questionnaires/evaluation form/cry diary and
microbial, vaginal and hair samples will be
recorded by the CI on CRFs and Microsoft
Excel spreadsheet charts throughout the study
(see also “Strategies to improve adherence to
intervention protocol for information”).
4. Participants’ impressions and experiences:
participants will be requested by the CI to fill in
a self-created evaluation form within 1 week after
completion of the pilot trial at home. The
questionnaire includes nine questions: five
questions on how the woman experienced
(1) filling in questionnaires during the pilot
trial (i.e. length, number of questionnaires,
electronic method), (2) collecting their own
and infant stool samples and vaginal samples
(i.e. number of samples, explanation about
method of collection, potential difficulties in
collecting samples) and (3) having hair samples
collected. Four items measure level of satisfaction:
two open-ended questions stating “Regarding the
study in general, which aspects did you experience
as most positive and negative?” and “Do you have
any general remarks regarding execution and
organization of this study?”. For the other two
questions, participants rate the perceived
burden of the trial on a scale of 0–10
(0 “no burden”, 10 “very large burden”) and
likelihood of participating in a similar trial in
the future (0 “no chance of future participation”,
10 “very high chance of future participation”).
Primary outcome: qualitative
Data collection for qualitative outcomes will consist of
face-to-face and telephone interviews conducted by the
CI. At the end of the home visit at baseline (t0), the CI (a
physician experienced in research and patient consulta-
tions) will ask participants face-to-face the timing and rea-
sons for deciding to join the study (“When did you make
the decision to join the PIP pilot trial?” “Why did you
choose to join the PIP pilot trial?”). Responses will be
noted and directly checked by participants for accuracy.
To determine the reasons for non-participation , the CI
will ask women who refuse to participate by telephone
their reason(s) for non-participation. Responses will be di-
rectly transcribed by the CI and not audiotape-recorded.
Microsoft Excel spreadsheet charts will be created with
(refusing and participating) women (in the rows) and re-
cruitment outcomes (in the columns).
Secondary outcomes
In addition to the primary objective, this pilot trial
includes six secondary objectives to ensure that certain
data can be collected and to exploratorily assess whether
maternal probiotic intake, compared to placebo, poten-
tially has an effect on (1) depressive and/or anxiety
symptoms, (2) maternal stress (i.e. reported and hair cor-
tisol), (3) maternal vaginal and intestinal microbiota, (4)
maternal bonding to offspring, (5) infant microbiota and
(6) infant crying. In the absence of a core outcome set to
measure potential effectiveness of probiotics on maternal
mood, we choose outcome measures that have shown
good psychometric properties and have been previously
used to assess depressive symptoms, anxiety and stress
in RCTs including non-pregnant [6, 28] and pregnant
women [36]. Similarly, outcome measures used to assess
maternal bonding to offspring and infant crying have
been shown reliable in previous studies [36–38]. Regard-
ing the rationale for the choice of biological outcomes,
please see “Discussion”. Given that the main aim of this
pilot trial is to assess feasibility and acceptability, and
not probiotic effectiveness, no criteria will be set for
comparison of treatment success between the two treat-
ment arms (probiotic versus placebo) for any of the
secondary outcomes. Figure 1 shows the secondary out-
comes measured throughout the study. Table 2 displays
the secondary outcome measurement variables, partici-
pant level analysis metric and methods of aggregation at
specific measurement time points of interest. Participants
will fill in all questionnaires electronically, except for the
Baby’s Day Diary, in order to improve data accuracy and
the timelines for receiving data. For data collection forms
(instructions and CRFs) see Additional file 2A-E.
Psychological parameter for screening
Suicidality risk
The Mini International Neuropsychiatric Interview (MINI)
is used to determine a positive diagnosis according to the
main Diagnostic and Statistical Manual (DSM)-III-R/IV
Axis I disorders. The Dutch translation [39] of the
clinician-rated version of the MINI will be used [40]. The
Dutch translation has had good validity in previous studies
[41, 42]. Suicide risk will be measured using six screening
questions from this tool. High suicidal risk is defined as a
positive response on questions C4 or C5 or (C3 +C6) [40].
Psychological parameters for secondary objectives
Maternal depression
Edinburgh Postnatal Depression Scale Symptoms of
depression are measured pre and post intervention
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Table 2 Secondary outcome measurement variables, participant level analysis metric and methods of aggregation at specific
measurement time points of interest
Secondary outcome Measurement variable Participant-level analysis
metrica
Method of aggregation for each
probiotic/placebo treatment arm
Demographic
information
History of atopy (mother) Baseline value Proportion of participants with positive history
of atopy at baseline
History of atopy (father) Baseline value Proportion of fathers with positive history of
atopy at baseline
History of psychiatric disorders Baseline value Proportion of participants with positive history
of depression or anxiety disorder at baseline
Number of previous pregnancies Baseline value Mean (SD) at baseline
Age Baseline value Mean (SD) at baseline
Number of previous children Baseline value Mean (SD) at baseline
Type of marital status Baseline value Proportion of participants in relationship
(i.e. married/living together) at baseline
Employment status Baseline value Proportion of participants employed
at baseline
Education level Baseline value Proportion of participants with primary
school, lower secondary vocational education,
lower secondary education, higher secondary
education, middle level vocational education
or tertiary education at baseline
Ethnicity Baseline value Proportion of participants whose fathers and
mothers were born in the Netherlands at baseline
Current psychiatric diagnosis Baseline value Proportion of participants with diagnosis
depression, anxiety disorder, none or other
at baseline
Breastfeeding Exclusive or partial breastfeeding End value Proportion of participants with exclusive
breastfeeding and partial breastfeeding
at 4 weeks postpartum (t4)
Maternal medication
use and treatment
Number of non- pharmacological
treatment(s) (i.e. cognitive behavioral
therapy, psychotherapy, rapid
eye-movement therapy, psychosocial
support)
Baseline value; change
from baseline to t1
Proportion of participants receiving
non-pharmacological treatment at baseline;
proportion of participants starting new
non-pharmacological treatment between
t0 and t1
Number of pharmacological treatment(s)
for depression or anxiety
Baseline value; change
from baseline to t1
Proportion of participants receiving
antidepressants, anxiolytics, other; proportion
of participants starting new pharmacological
treatment(s) for depression or anxiety
between t0 and t1
Type of general medication used Baseline value; change
from baseline to t1
Proportion of participants taking medication
(other than pharmacological treatment for
depression or anxiety); proportion of
participants who start taking new medication
between t0 and t1
Type of food supplement(s) used Baseline value; change
from baseline to t1
Proportion of participants taking food
supplements; proportion of participants who
start taking new food supplements during the
intervention period
Type of vitamin(s) used Baseline value; change
from baseline to t1
Proportion of participants taking vitamins;
proportion of participants who start taking
new vitamins during the intervention period
Maternal lifestyle Smoking (yes/no) Baseline value Proportion of participants smoking
Alcohol (yes/no) Baseline value Proportion of participants drinking alcohol
Pregnancy
characteristics
Occurrence of infections during pregnancy Final value Proportion of participants reporting infections
(i.e. influenza, fever, diarrhea) throughout the study
Delivery
characteristics
Gestational age Final value Gestational age at delivery
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through the Edinburgh Postnatal Depression Scale
(EPDS). The EPDS is a validated tool that screens for
antenatal and postnatal depressive symptoms [43]. It con-
sists of 10 items related to how the participant has felt over
the past 7 days rated on a 4-point scale. The Dutch transla-
tion of the questionnaire has demonstrated excellent psy-
chometric properties, including high test-retest reliability
and concurrent validity among pregnant women in the
Netherlands [44]. A sum score of 10 or more is believed to
represent the presence of mild depressive symptoms as de-
termined in a Dutch antenatal sample, yielding respectively
70% and 96% sensitivity and specificity [44].
Leiden Index of Depression Sensitivity-Revised This
measure is included because an earlier study using the
Leiden Index of Depression Sensitivity-Revised (LEIDS-R)
found that the intake of probiotics significantly reduced
negative thoughts associated with sad mood [28]. The
LEIDS-R is a validated tool that measures perceived cog-
nitive reactivity to sadness, as a predictor of depression
and will be applied in its original language (Dutch) [45–
47]. The 34-item self-report includes six subscales:
hopelessness/suicidality, acceptance/coping, aggression/
hostility, control/perfectionism, risk aversion and rumin-
ation. Participants rate the extent to which each statement
Table 2 Secondary outcome measurement variables, participant level analysis metric and methods of aggregation at specific
measurement time points of interest (Continued)
Secondary outcome Measurement variable Participant-level analysis
metrica
Method of aggregation for each
probiotic/placebo treatment arm
Pregnancy and
delivery complications
Number of pregnancy and delivery
complications (i.e. hypertensive disorders
of pregnancy (pregnancy induced
hypertension, preeclampsia, eclampsia,
hemolysis - elevated liver enzymes - low
platelet count (HELLP) syndrome), gestational
diabetes mellitus, preterm birth, cesarean
section, retention placentae, hemorrhage
postpartum, small or large for gestational
age (birth weight < p10 or > p90), puerperal
fever, prolonged labor, premature
rupture of membranes)
Final value Proportion of participants diagnosed with
pregnancy or delivery complications at delivery
Infant antibiotic use Number of antibiotics used Final value Proportion of infants receiving
antibiotics during first month of life
Depression Edinburgh Postnatal Depression Scale
(EPDS) score
Change from baseline to
t1 and t4
Mean (SD)/median (IQR)
Depression/cognitive
reactivity
Leiden Index of Depression
Sensitivity-Revised (LEIDS-R) score
Change from baseline to
t1 and t4
Mean (SD)/median (IQR)
Pregnancy related
anxiety
Pregnancy Related Anxiety
Questionnaire-Revised (PRAQ-R) score
Change from baseline to
t1
Mean (SD)/median (IQR)
General anxiety State-trait Anxiety Inventory (STAI-S) score Change from baseline to
t1 and t4
Mean (SD)/median (IQR)
Pregnancy-related
daily hassles
Pregnancy-related daily hassles
(PES) score
Change from baseline to
t1 and t4
Mean (SD)/median (IQR)
General daily
hassles/stress
Daily Hassles List (APL) score Change from baseline to
t1 and t4
Mean (SD)/median (IQR)
Mother to infant
bonding
Maternal Antenatal Attachment Scale
(MAAS) score
Change from baseline to
t1
Mean (SD)/median (IQR)
Maternal Postnatal Attachment
Scale (MPAS)
Change from t3 to t4 Mean (SD)/median (IQR)
Biological samples Maternal fecal samples (microbiota) Change from baseline to
t1
Relative abundance and diversity
of bacteria at phylum up to genus level
Maternal vaginal samples (microbiota) Change from baseline to
t1
Relative abundance and diversity
of bacteria at phylum up to genus level
Maternal hair (cortisol) Change from baseline to
t1
Mean (SD)/median (IQR)
Fecal sample infant (microbiota) Change from t3 to t4 Relative abundance of bacteria at
phylum up to genus level
Cry diary Duration (hours/minutes) of crying
during 3 days
Final value Mean (SD)/median (IQR)
aBaseline: t0; time point 1: t1, time point 3: t3, time point 4: t4
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applies to them on a 5-point scale, ranging from “not
at all” to “very strongly”. A higher total score indi-
cates stronger cognitive reactivity.
Maternal anxiety
Pregnancy Related Anxiety Questionnaire-Revised
Pregnancy-specific anxiety is measured using the Preg-
nancy Related Anxiety Questionnaire-Revised (PRAQ-R).
The PRAQ-R is a validated 10-item tool that screens for
pregnancy-related anxiety in pregnant women and will be
applied in its original language (Dutch) (Cronbach’s alpha
between 0.79 and 0.88) [48]. Questions concern specific
fears and worries related to pregnancy It is a shortened
version of the 34-item questionnaire [49]. The PRAQ-R
consists of three subscales: “fear of bearing a physically or
mentally handicapped child” (“child-related anxiety”, 4
items), “fear of giving birth” (3 items) and “concern about
one’s appearance” (3 items). Scales range from 1 (abso-
lutely not relevant) to 5 (very relevant). The PRAQ-R has
no established cutoff point; higher scores indicate higher
levels of anxiety.
State-trait Anxiety Inventory General anxiety is mea-
sured using the State-trait Anxiety Inventory (STAI-S).
This self-report questionnaire evaluates prenatal anxiety
in women [50] and the Dutch translation has good vali-
dity and reliability [51]. The STAI-S consists of 20 state-
ments related to feelings of anxiety. Women indicate
how they feel at the present moment on a 4-point scale.
Scores are summed up and higher scores imply more
general feelings of anxiety. A cutoff > 40 in STAI has
80.95% and 79.75% sensitivity and specificity in the third
trimester of pregnancy to detect anxiety disorder [52].
Maternal stress
Pregnancy-related daily hassles Pregnancy-specific daily
hassles/stress are assessed with the Dutch translation of
the Pregnancy Experience Scale (PES), a 43-item self-
report inventory that measures maternal appraisal of daily,
pregnancy-specific hassles and uplifts (Cronbach’s alpha
between 0.91 and 0.95 when applied in its original
language) [53]. The Dutch translation has been commonly
used among pregnant Dutch women [54, 55]. Women rate
the degree to which specific experiences constitute a has-
sle and uplift on a 5-point scale. The total score is the
sum of intensities of hassles divided by the sum of inten-
sities of uplifts; higher values indicate greater negative
emotional bearing towards pregnancy hassles.
General daily hassles/stress General daily hassles/stress
are evaluated using the Dutch Algemene Problemen Lijst
(Everyday Problem List) (APL). The APL measures the rate
of occurrence and (negative) valence of daily hassles in the
past 2months (test–retest reliabilities between 0.76 and 0.87
among Dutch mothers) [56]. The APL consists of 49-items
rated on a 4-point Likert scale. The total sum of the extent
to which daily hassles bothered participants is divided by
the frequency of daily hassles. Higher scores indicate more
perceived stress due to daily hassles by the individual.
Mother-to-infant bonding
The Maternal Antenatal Attachment Scale The Maternal
Antenatal Attachment Scale (MAAS) assesses a mother’s
bonding with her fetus. Previous studies have shown good
psychometric properties of the Dutch translation in Dutch
pregnant women [57]. The MAAS consists of 19 items
divided into two subscales: “quality of attachment” (11
items) and “intensity of preoccupation” (8 items). Scales
range from 1 (low bonding) to 5 (high bonding) [58].
Higher sum scores reflect higher-quality bonding and
greater preoccupation with the unborn child.
The Maternal Postnatal Attachment Scale The
Maternal Postnatal Attachment Scale (MPAS) assesses
the strength of the mother-to-infant bonding. The Dutch
version of the MPAS has been demonstrated to be a
valid and reliable tool for use in Dutch women during
the postnatal period [59]. The MPAS questionnaire
consists of 19 items, divided over three subscales: “qua-
lity of attachment”, “absence of hostility” and “pleasure
in interaction” [60]. Women score the items on a
5-point Likert scale: 1 (low bonding) to 5 (high bond-
ing). A higher sum score on the MPAS indicates higher
quality mother-to-infant bonding.
Behavioral parameter
Infant crying
Baby’s Day Diary Barr’s standardized 24-h behavior
diary to record infant crying, fussing and unsoothable
crying will be used at 4 weeks of age for 3 days conse-
cutively [61]. Barr’s behavior diary has been widely used
and is validated against audio recordings with satisfac-
tory results [61, 62]. The Dutch translation of the Baby’s
Day Diary has been previously used in research [37, 38].
Mothers will fill in the Baby’s Day Diary at home on 3 days
consecutively and will send a digital copy of the diary to
the investigators. Excessive crying is determined as crying
for ≥ 3 h per day on 3 constituent assessment days, to
investigate the clinical implications of the results [63].
Biological parameters
Maternal hair cortisol
A strand of around 50 hairs per person will be collected
from the posterior vertex [64] at 4 weeks for postpartum
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cortisol analysis, in concordance with previously vali-
dated methods of collection and analysis of hair. The CI
will cut the hair with scissors, as close as possible to the
participant’s scalp. The hair closest to the scalp repre-
sents the most recent part of pregnancy. The sampling
site is not visible afterwards, as the hair growing above
covers it. After collection, 1 cm of the strand of hair that
was closest to the scalp will be removed. The strand will
then be divided into two segments for analysis, re-
presenting (1) the period during the last 8 weeks of pro-
biotic or placebo intervention (2 cm) and (2) 2 months
before the intervention (2 cm). Hair grows appro-
ximately 1 cm a month and therefore 2 cm will cover 8
weeks of probiotic or placebo intake. Hair cortisol
will be analyzed using the procedure described by
Manenschijn, Koper, Lamberts & van Rossum in 2011
[64]. A correction factor will be applied to account for the
potential influence of differences in hair weight. Par-
ticipants will record on a data form any intake of oral
corticosteroids during pregnancy and other potential
confounding factors. The hair and accompanying form
will be securely stored together with the hair sample at
the Sponsor’s site.
Maternal vaginal microbiota
Two vaginal samples will be collected to study changes
in vaginal microbiota between baseline and 8 weeks after
the start of the intervention. Participants will collect the
samples by rotating swabs 3–4 cm deep into the vagina.
Samples will be collected by the validated self-collection
method using dry swabs [65]. The samples will be im-
mediately stored at − 20 °C, collected by investigators
at t1 or t4 and then stored at − 80 °C at the Radboud
University. Microbial composition will be determined
using polymerase chain reaction (PCR) sequencing
methods at affiliated universities experienced in this
type of analysis; the location for these analyses has
yet to be determined.
Maternal intestinal microbiota
Participants will collect fecal samples twice using
collection methods applied in our previous studies
[36, 38], in order to study changes in maternal intestinal
microbiota between baseline and 8 weeks after the start of
the intervention. For storage procedures, see “Maternal
vaginal microbiota”.
Infant intestinal microbiota
Parents will collect two infant fecal samples at home on
weeks 1 and 4 using similar collection methods to those
applied in our previous studies [36, 38], to measure the
relative abundance of infant intestinal bacteria. Samples
will be immediately stored by the participants at − 20 °C,
collected by investigators at t3 and taken back to the
University for storage at − 80 °C. The microbial com-
position of the stool samples will be analyzed using PCR
sequencing methods.
Possible confounding variables
Maternal sleep and stressful events will be measured
throughout the study period, as both factors may in-
fluence the intestinal microbiota in mothers and infants,
as well as maternal mood [55, 66, 67].
Pittsburgh Sleep Quality Index
Sleep quality is measured using the Pittsburgh Sleep
Quality Index (PSQI), a self-rated questionnaire that
assesses sleep quality and disturbances during the pre-
vious months [68]. The PSQI has demonstrated good psy-
chometric properties, including good internal consistency
and validity in pregnant women [69]. We will use the
Dutch translation of the PSQI, which has been commonly
used in Dutch populations [36, 70]. The sum of scores
ranges between 0 and 21 and scores ≤ 5 and > 5 indicates
“poor sleepers” and “good sleepers”, respectively [68].
Stressful events questionnaire
Other systematic reviews have noted the stressful events
that can predict prenatal anxiety and depression [71, 72].
Based on these studies, we constructed a new stressful
events questionnaire that assesses whether or not parti-
cipants experienced one or more stressful events during
the past 12 months. The questionnaire includes 8 items
(i.e. death of a close relative/family member, financial
problems, divorce etc.) on a dichotomous scale (yes/no).
More reported stressful events indicates higher inci-
dence of stressful events.
Adherence assessment
To facilitate adherence to the study protocol and increase
the validity of data, throughout the study the CI will
inquire about participants’ experiences during the trial,
including potential problems with the probiotic/placebo
product intake, questionnaires and collection of vaginal
and stool samples. In the case of problems, the CI will dis-
cuss solutions with the participants to improve adherence.
After 8 weeks of probiotic intake (t1) the CI will call to
inform the participant about the number of sachets
consumed during the intervention period and will record
the number on the CRF. At t4, the CI will measure
compliance during a home visit by counting the sachets
that are left from the previous weeks and notes the data
on the CRF. Electronic questionnaire data collected from
participants will be downloaded into a designated secure
Radboud University study computer to check for missing
data. In the case of missing questionnaire data, the CI will
send an e-mail reminder to the participant with the
request to fill in the questionnaire as soon as possible. The
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CI will record non-adherence and non-retention (i.e. con-
sent withdrawn and loss to follow up) on the CRFs, and
the reasons for non-adherence and non-retention if the
participants are willing to reveal these.
Strategies to improve adherence to the intervention
protocol
During the first home visit when the participants receive
the probiotic/placebo product and sampling kits, the CI
will provide face-to-face adherence reminder sessions.
Similar adherence reminder sessions will be held by phone
at t1 and t3, and face-to-face at t4. This will include:
1. Explanation about the importance of adhering
to study guidelines on the daily intake of the study
product, electronic questionnaires and collection
of vaginal and microbial sampling.
2. Instructions about taking the probiotic/placebo
product, including timing, preparation, storage,
and what to do in the event of missing a dose.
3. Reinforcement that the sachets contain either
probiotics or placebo.
4. Instructions about the purpose and use of
vaginal swabs and microbial collection tubes,
and temporary storage of vaginal and microbial
specimens after collection. Instructions on paper
will be provided at t0 (see Additional file 3D-E).
5. Notification of the importance of contacting the
CI if experiencing any problems related to intake
of the probiotic/placebo product (e.g. symptoms,
lost sachets), electronic questionnaires or the
collection of vaginal and/or microbial samples.
6. Reinforcement that, if there are any questions
related to the study or problems occur during
the intervention period, the CI (or in case of
absence, another research member) can be
contacted by phone or e-mail.
Within 2 days after the first home visit, the CI will
contact the participant to ask whether there were any
problems with the probiotic/placebo product or ques-
tionnaires, and to inform them about the time/date of
collecting vaginal and stool samples. In case there are
problems, simple strategies for enhancing adherence
to study protocol will be discussed. The participant
will also have the opportunity to ask the CI any
remaining questions.
Participants will receive an electronic reminder at t1
to fill in questionnaires and to collect vaginal and micro-
bial samples, again including the instructions about the
use of vaginal swabs and microbial tubes and storage of
specimens after collection. The CI will contact the
participant 2 days after the first reminder, to request the
time/date of collection of microbial and vaginal samples.
In the case of problems, the CI will discuss with the
participant simple strategies to enhance collection
and/or filling in of questionnaires.
Plans to promote participant retention and complete
follow up
Several methods will be applied to promote participant
retention, including financial reimbursement (€65) and
by limiting participant burden (i.e. by conducting home
visits and by allowing participants who decline specific
assessments for one outcome to continue with assess-
ments for other follow-up outcomes).
Training and certificates of investigators
To promote consistency in data collection and enhance
data quality, the CI and Research Physician will be
trained in medical scientific research, legislation and
regulation to carry out clinical research. Passing the
national examination of the basic course for clinical
investigators (BROK®) will certify their competencies as
clinical investigators. Additionally, the CI will be trained
in standardized collection of hair samples at Radboud
University, will receive training at the Amsterdam
University Medical Centers on entering information on
to the CRFs and responding to data discrepancies and
training in qualitative research at the Vrije Universiteit
Amsterdam.
Data management
Data recorded on paper forms (e.g. Baby’s Cry Diary)
will be entered into the computer by data entry
personnel at the Sponsor site, using double data entry.
Researchers who score the duration of crying diaries will
be blinded to the treatment arms. Data integrity on
Microsoft Excel spreadsheet charts will be enforced
through referential data rules, range and consistency
checks against data already present in the database.
Independent source document verification of a random
subset of CRFs will be performed to detect data entry
errors. Data recorded on paper (e.g. CRFs) will be securely
stored in numerical order at the Radboud University.
Electronic data (i.e. online questionnaires and electro-
nically entered data from CRFs) will be stored on the
university server using password-protected access systems
only known to the trial committee researchers and
research assistants. Data backup will be performed daily.
Hair and biological samples will be retained at the
Sponsor site until the study is completed and then sent to
collaborative universities for analysis through secure
mail. In concordance with Good Clinical Practice
(GCP) guidelines, electronic data and informed consent
forms will be retained for at least 15 years after comple-
tion of the pilot study.
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Statistical analysis
Primary quantitative outcomes
The primary outcomes, (A) recruitment, (B) retention
rate, (C) compliance and (D) (1–5) participants’ impres-
sions and experiences, will be descriptively analyzed and
visualized in tables or graphs: number and percentages
will be calculated for categorical variables and mean (or
median) and SD (or IQR) will be calculated for conti-
nuous variables. For outcome (D) (1–3), participants’
impressions and experiences, the main themes and
categories of participants’ responses will be identified
(see “Primary qualitative outcomes” for description of
conventional content analysis and the framework ap-
proach) and quantified [73, 74]. The prevalence of coded
themes will be calculated as a percentage of the total
number of identified coded themes. Demographic data on
subjects (general health, socio-economic factors, etc.) will
be tabulated.
Primary qualitative outcomes
Qualitative content analysis following principles of the
framework approach will be undertaken for outcome (A)
recruitment [73, 74]. To develop an analytical frame-
work, two researchers will read through all answers from
Microsoft Excel spreadsheet charts and will apply in-
ductive “open coding” (i.e. label what they consider to be
relevant from as many perspectives as possible). After
coding the first transcripts, the labels applied will be
compared between the two researchers to agree on a set
of codes and these codes will be grouped to form themes
and categories. The analytical framework, including the
codes and themes, will consequently be used to index all
transcripts. Data will be summarized by category and
put into a Microsoft Excel spreadsheet chart to generate
a matrix. The chart consists of participants (rows) and
emergent qualitative themes (columns) and will be used to
identify similarities and differences between participants’
expressed thoughts. The qualitative findings will be de-
scribed in detail, supported by quotes from participants.
Secondary outcomes
Although the aim of this pilot trial is to assess the feasibi-
lity and acceptability of running a definitive trial, the se-
condary psychological, behavioral and biological outcomes
will be analyzed to mimic the definitive trial. All analyses
of the secondary outcomes will hence be viewed as
preliminary and thus interpreted with caution.
Outcomes will be analyzed per-protocol and by
intention to treat (ITT). For the per-protocol analysis,
participants who are found ineligible after randomization
or deviated from the probiotics/placebo product intake
(i.e. less than 80% intake) will be excluded from the
main analysis. For the ITT analysis, all randomized par-
ticipants, regardless of protocol adherence or dropouts
(i.e. participants who withdraw consent for continued
follow up), will be included in the main analysis. Partici-
pants will be analyzed according to the group to which
they were originally allocated. In case of missing
data, missing values will be imputed. Student’s t test will
be used to analyze normally distributed data and the
nonparametric Mann–Whitney U test will be used to
analyze non-normally distributed data. For comparisons
of more than two groups (e.g. differences in the relative
abundance of bacteria at the level of phylum up to the
level of order in microbial samples), analysis of variance
with Tukey’s post-hoc test of the intervention and pla-
cebo group at the primary endpoint will be compared
using a one-way analysis of covariance (ANCOVA)
model, where the covariate will be the baseline score. In
addition, the effect size will be computed to estimate the
required sample size for the future large-scale trial. The
significance level for statistical analysis is set at p < 0.05.
Data monitoring and auditing
The Sponsor will appoint a monitor independent of the
investigators, who will visit the trial site before initiation
of the study and once during the recruitment of parti-
cipants. The monitor will check on adherence to the
study protocol, reporting of adverse events (AEs) and
CRFs, verification of the completeness of the trial master
file and the quality and completeness of the data, and
will examine source documents and determine whether
the data reported in the Microsoft Excel spreadsheet
charts are accurate. Given the expected relatively short
duration of the pilot study and that this trial was catego-
rized as minimal-risk research by the Medical Ethics
Committee (METC), no official data monitoring com-
mittee will be installed to periodically review the accu-
mulating data or to determine whether the pilot should
be modified or discontinued.
Potential harms
We consider this study to pose negligible risk to partici-
pants. Participants in the probiotic arm may experience
incidental sensations of bloating and change in stool
consistency [75–81]. In accordance with the principles
of the Declaration of Helsinki (64th WMA General As-
sembly, Fortaleza, Brazil, October 2013), we will under-
line to the participants that they can leave the study at
any time for any reason if they wish to do so, without
any consequences.
By filling in the questionnaires on symptoms of
depression, anxiety and stress, participants may become
more aware of these symptoms, therefore, become more
anxious or depressed. In the occurrence of a psychiatric
emergency, as observed during telephone or personal
contact, the treating physicians (gynecologist, midwife,
psychiatrist or general practitioner) will be informed as
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soon as possible (within < 12 h) about the health status
of their patient, in order to take appropriate measure-
ments. Furthermore, if a woman scores positively (e.g.
“sometimes” or “yes, quite often”) on question 10 of the
EPDS (“The thought of harming myself has occurred to
me”), she will be advised by the CI to contact her
general practitioner for support. Additionally, as stated
previously, when a woman screens positive for “high
risk” on suicidality (MINI), the woman’s general practi-
tioner will be informed about the outcome of the MINI
interview within a maximum of 12 h.
Amendments
Any amendments of the protocol, including changes to
study objectives, primary outcomes, study design, sub-
ject population, sample size or other study procedures
that may impact the conduct of the study, need to be ap-
proved by the METC of the Radboud university medical
center in Nijmegen. Non-substantial amendments,
including minor corrections and/or clarifications that
have no effect on the way the study is conducted, will
not be notified to the accredited METC; these non-sub-
stantial amendments will be recorded and filed by the
Sponsor.
Confidentially
Data records containing personal participant information
(e.g. informed consent forms) will be locked in file
cabinets with limited access and kept separate from other
study records identified by coded identification (ID),
including the Baby's Cry Diary and other forms that
link data to participants, to maintain participant con-
fidentiality. Laboratory specimens will be coded with
similar IDs (PIP01, PIP02, etc.) and kept in freezers
with limited access. Electronic databases will be se-
cured with password-protected access systems. Trial
committee members will keep all results on question-
naires strictly confidential, and will only provide in-
formation to others on scores and the prevalence of
anxiety and depression at the population level. Biological
specimens transmitted via secure mail to collaborative
universities for analysis are coded, and researchers at
the collaborative universities will not have access to
the subject ID code. All biological specimens will be
destroyed after analysis.
Access to data
Only members of the Trial Steering Committee and the
supporting Research Assistant will have access to the final
dataset. Investigators who are to conduct biological ana-
lysis will only have access to data by request and after
approval by the Steering Committee. Data dispersed to
collaborative investigators will be blinded to participants’
personal information.
Serious adverse events
In accordance with the legal regulations of the METC and
International Conference on Harmonization (ICH)-GCP
regulations, the PI will report the serious adverse events
(SAEs) to the accredited METC that approved the proto-
col, within 7 days of first knowledge of SAEs that are life
threatening or result in death, followed by a period of a
maximum of 8 days to complete the initial preliminary
report. The PI will report all other SAEs to the METC
within a period of a maximum of 15 days after the
Sponsor has first knowledge of the SAEs.
Premature termination of the study
The study will be terminated prematurely in the case of
serious safety issues for participants. In the case that the
study is ended prematurely, the PI will notify the accre-
dited METC and the competent authority within 15 days,
including the reasons for the premature termination.
Ancillary and post-trial care
In accordance with the legal requirements in the
Netherlands (Article 7 WMO and the Measure regard-
ing Compulsory Insurance for Clinical Research in
Humans of 23 June 2003), the Radboud University’s
insurance will cover any potential injury that may be
caused by the study.
Dissemination policy
Members of the Steering Committee will analyze the
data and write the final paper. The researchers will com-
ply with the basic principles of the METC position on
the disclosure/publication of research results obtained
from studies involving human subjects: the results will
be publicly disclosed without any restrictions; both
positive and negative results will be published in a
peer-reviewed journal. If the results are not eligible for a
peer-reviewed publication, the research results will be
publicly disclosed in the trial registry database. The
researchers will undertake every attempt to reduce the
minimum interval between completion of data collection
and release of the results to participants and partici-
pating centers. We expect to share the first results (i.e.
questionnaire data) with participants and participating
centers within 3 months after completion of the study;
we expect to share the results of analysis of biological
specimens and to send the final paper to a journal
within 1 year after study completion.
Authorship
All research investigators of this pilot trial who provided
substantial contributions to the design, conduct, analysis,
interpretation and reporting of the study will be granted
authorship on the final paper.
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Data sharing statement
The anonymized participant-level dataset and statistical
codes to generate results will be made available upon rea-
sonable request directly after acceptance of the final paper.
Discussion and conclusion
Many expectant mothers experience symptoms of depres-
sion and anxiety during pregnancy, which can affect both
the mother and the infant [1, 82, 83]. Most women remain
untreated: only 14% of women with symptoms of prenatal
depression or anxiety receive treatment [2].
There is a great need for accessible and effective (com-
plementary) treatments that can be applied during preg-
nancy. There are indications that probiotics ingested
during and after pregnancy can reduce symptoms of
depression and anxiety postpartum [14]. Probiotics
ingested by the mother may thus offer a promising and
user-friendly intervention to complement current exist-
ing effective treatments aimed at reducing symptoms of
anxiety or depression during pregnancy. The present
study is the first study to investigate the feasibility and
acceptability of a probiotic trial to reduce symptoms of
maternal prenatal depression or anxiety in pregnant
women. Results of this pilot trial will help make an
informed decision whether or not to proceed with a full
trial after the pilot trial, and if so, whether revisions
should be made to the study protocol and procedures
before conducting a full RCT.
Potential underlying mechanisms
The influence of gut microbiota on maternal mood
would be facilitated by the microbiota-gut-brain (MGB)
axis. This bidirectional pathway integrates neural, im-
munological and hormonal signaling pathways between
the gut and the brain [84, 85]. Microbial gut dysbiosis,
an altered state of the gut microbiota composition, has
been linked to anxiety and depression in pregnant and
non-pregnant individuals [8, 9, 86, 87]. Probiotics, with
their anti-inflammatory and neuroregulatory properties,
may improve gut microbiota composition and function-
ing in pregnant mothers [10, 14, 88]. In turn, this may
reduce symptoms of anxiety and depression [6, 14].
Furthermore, probiotics may also influence vaginal
microbiota. Prenatal maternal stress has been linked to
vaginal dysbiosis [89], and a state of vaginal dysbiosis
can be positively influenced by maternal oral intake of
probiotics [90].
Maternal stress (i.e. reported and hair cortisol)
Next to potentially reducing symptoms of anxiety or
depression, maternal prenatal probiotic intake may also
decrease maternal stress (i.e. reported and hair cortisol).
There are indications that stress is associated with an
imbalance in intestinal microbiota, and that the
ingestion of probiotics may restore such imbalance [91,
92]. For example, a study in healthy volunteers showed
that probiotic ingestion resulted in lower levels of self-
reported stress [86].
Additionally, the hypothalamic-pituitary-adrenal (HPA)-
axis is highly activated in mothers with symptoms of
stress, anxiety or depression, leading to elevated levels of
cortisol, which accumulates in hair [93–96]. Since hair
grows ~ 1 cm a month, higher concentration of hair
cortisol is suggested to reflect the long-term activation
of the maternal HPA-axis during pregnancy [96–101].
Maternal bonding to offspring
Maternal prenatal probiotic intake may influence maternal
prenatal and early postnatal bonding to offspring by im-
proving maternal mood. Indeed, lower levels of maternal
depression have been associated with greater maternal
bonding to infants [102, 103].
Maternal vaginal and gut microbiota
Previous studies suggest that maternal stress during
pregnancy is associated with vaginal [89] and intestinal
dysbiosis [87]. The collection of maternal vaginal and
gut microbiota samples will help determine whether
mothers receiving a probiotic have vaginal and microbial
compositions characterized by more beneficial bacteria,
compared to mothers in the placebo group.
Infant microbiota and crying
Maternal prenatal depression or anxiety does not only
affect the mother, but also her infant. Maternal prenatal
probiotic intake, by improving maternal mood, may be
beneficial for the infant in improving infant intestinal
microbiota and reducing infant crying. For instance,
maternal prenatal stress has been related to changes in
infant intestinal microbiota [55] and increased crying
behavior in infants [104–106]. Infants of mothers with
high levels of prenatal stress were found to have higher
relative abundance of pathogenetic bacteria and lower
relative abundance of beneficial bacteria (i.e. lactobacilli
and bifidobacteria), compared to mothers with low levels
of stress [55]. Increased levels of pathogenic intestinal
bacteria and reduction in beneficial bacteria have been
associated with excessive crying in infants [38]. Hence,
we postulate that symptoms of maternal prenatal anxiety
or depression may cause intestinal microbial imbalances
in infants, and that this in turn may contribute to exces-
sive crying.
To date, most studies have focused on the effects of
probiotics on maternal mood during the postnatal
period [6, 14]. No studies have examined the effects of
probiotics on maternal mood during pregnancy. If a
probiotic intervention during pregnancy is shown to be
feasible and acceptable, combined with preliminary results
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indicating plausible effectiveness to improve maternal
prenatal mood, evaluating of the effectiveness of pro-
biotics on maternal prenatal mood in a large RCT would
be warranted.
Trial status
Protocol Version 03 (19 October 2016). At the time of
submission, 35 participants had signed the informed
consent form (18 of them have completed the study
protocol). Recruitment started in March 2017; the first
participant was enrolled in May 2017.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist. (DOC 121 kb)
Additional file 2: WHO Trial Registration Data Set. (DOCX 118 kb)
Additional file 3: A-E. Related documentation given to participants.
(ZIP 942 kb)
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